These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 9546285)

  • 1. Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL.
    Cobbers JM; Wolter M; Reifenberger J; Ring GU; Jessen F; An HX; Niederacher D; Schmidt EE; Ichimura K; Floeth F; Kirsch L; Borchard F; Louis DN; Collins VP; Reifenberger G
    Brain Pathol; 1998 Apr; 8(2):263-76. PubMed ID: 9546285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma.
    Møller MB; Ino Y; Gerdes AM; Skjødt K; Louis DN; Pedersen NT
    Leukemia; 1999 Mar; 13(3):453-9. PubMed ID: 10086736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas.
    Nakamura M; Sakaki T; Hashimoto H; Nakase H; Ishida E; Shimada K; Konishi N
    Cancer Res; 2001 Sep; 61(17):6335-9. PubMed ID: 11522621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type.
    Hayashi Y; Iwato M; Arakawa Y; Fujisawa H; Thoma Y; Hasegawa M; Tachibana O; Yamashita J
    J Neurooncol; 2001 Oct; 55(1):51-8. PubMed ID: 11804283
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Nayyar N; White MD; Gill CM; Lastrapes M; Bertalan M; Kaplan A; D'Andrea MR; Bihun I; Kaneb A; Dietrich J; Ferry JA; Martinez-Lage M; Giobbie-Hurder A; Borger DR; Rodriguez FJ; Frosch MP; Batchelor E; Hoang K; Kuter B; Fortin S; Holdhoff M; Cahill DP; Carter S; Brastianos PK; Batchelor TT
    Blood Adv; 2019 Feb; 3(3):375-383. PubMed ID: 30723112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A.
    Møller MB; Kania PW; Ino Y; Gerdes AM; Nielsen O; Louis DN; Skjødt K; Pedersen NT
    Leukemia; 2000 May; 14(5):898-904. PubMed ID: 10803523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG island methylation of tumor-related genes in three primary central nervous system lymphomas in immunocompetent patients.
    Gonzalez-Gomez P; Bello MJ; Arjona D; Alonso ME; Lomas J; Amiñoso C; de Campos JM; Sarasa JL; Gutierrez M; Rey JA
    Cancer Genet Cytogenet; 2003 Apr; 142(1):21-4. PubMed ID: 12660028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma.
    Braaten KM; Betensky RA; de Leval L; Okada Y; Hochberg FH; Louis DN; Harris NL; Batchelor TT
    Clin Cancer Res; 2003 Mar; 9(3):1063-9. PubMed ID: 12631608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
    Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R
    Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
    Nielsen GP; Burns KL; Rosenberg AE; Louis DN
    Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of genomic alterations in primary central nervous system lymphomas.
    Zorofchian S; El-Achi H; Yan Y; Esquenazi Y; Ballester LY
    J Neurooncol; 2018 Dec; 140(3):509-517. PubMed ID: 30171453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A.
    Elnenaei MO; Gruszka-Westwood AM; A'Hernt R; Matutes E; Sirohi B; Powles R; Catovsky D
    Haematologica; 2003 May; 88(5):529-37. PubMed ID: 12745272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular analysis of the Ink4a/Rb1-Arf/Tp53 pathways in radon-induced rat lung tumors.
    Bastide K; Guilly MN; Bernaudin JF; Joubert C; Lectard B; Levalois C; Malfoy B; Chevillard S
    Lung Cancer; 2009 Mar; 63(3):348-53. PubMed ID: 18656278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.
    Cui Y; Han L; Shang J; Fang W; Zhao M; Chen D; Liu H
    Hum Pathol; 2022 May; 123():113-122. PubMed ID: 35181378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas.
    Kaune KM; Neumann C; Hallermann C; Haller F; Schön MP; Middel P
    Exp Dermatol; 2011 Apr; 20(4):331-5. PubMed ID: 21410763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
    Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
    Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and Correlation of Single and Concomitant
    Pessôa IA; Amorim CK; Ferreira WAS; Sagica F; Brito JR; Othman M; Meyer B; Liehr T; de Oliveira EHC
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.
    Sanchez-Cespedes M; Reed AL; Buta M; Wu L; Westra WH; Herman JG; Yang SC; Jen J; Sidransky D
    Oncogene; 1999 Oct; 18(43):5843-9. PubMed ID: 10557071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
    Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
    Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma.
    Hattori K; Sakata-Yanagimoto M; Kusakabe M; Nanmoku T; Suehara Y; Matsuoka R; Noguchi M; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Muratani M; Hasegawa Y; Chiba S
    Cancer Sci; 2019 Jan; 110(1):401-407. PubMed ID: 30353605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.